Methylpromazine

CHEMBL829 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
298.4 g/mol
LogP
4.7
Phase
4

This phenothiazine derivative with sedative and antiemetic properties was used as an antipsychotic and to prevent nausea and vomiting, working by blocking dopamine receptors in the brain. It is one of many phenothiazine compounds that vary in their potency and side effect profiles.

Khối lượng phân tử

298,4000 g/mol

LogP

4,70

TPSA

31,80 Ų

Lipinski RO5

Đạt

Cơ chế tác dụng

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(CN(C)C)CN1c2ccccc2Sc2ccccc21

InChI

InChI=1S/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3

Molecular Formula

C18H22N2S

HBD / HBA

- / 3

Liên kết có thể quay

4

Nguyên tử nặng

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

This phenothiazine derivative with sedative and antiemetic properties was used as an antipsychotic and to prevent nausea and vomiting, working by blocking dopamine receptors in the brain. It is one of many phenothiazine compounds that vary in their potency and side effect profiles.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Methylpromazine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL829. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5574. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.